These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 26101239)

  • 1. Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.
    O'Sullivan CC; Bradbury I; Campbell C; Spielmann M; Perez EA; Joensuu H; Costantino JP; Delaloge S; Rastogi P; Zardavas D; Ballman KV; Holmes E; de Azambuja E; Piccart-Gebhart M; Zujewski JA; Gelber RD
    J Clin Oncol; 2015 Aug; 33(24):2600-8. PubMed ID: 26101239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
    Loi S; Dafni U; Karlis D; Polydoropoulou V; Young BM; Willis S; Long B; de Azambuja E; Sotiriou C; Viale G; Rüschoff J; Piccart MJ; Dowsett M; Michiels S; Leyland-Jones B
    JAMA Oncol; 2016 Aug; 2(8):1040-7. PubMed ID: 27100299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial.
    Partridge AH; Gelber S; Piccart-Gebhart MJ; Focant F; Scullion M; Holmes E; Winer EP; Gelber RD
    J Clin Oncol; 2013 Jul; 31(21):2692-8. PubMed ID: 23752109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-duration versus 1-year adjuvant trastuzumab in early HER2 positive breast cancer: A meta-analysis of randomized controlled trials.
    Chen L; Zhou W; Hu X; Yi M; Ye C; Yao G
    Cancer Treat Rev; 2019 May; 75():12-19. PubMed ID: 30856373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials.
    Niraula S; Gyawali B
    Breast Cancer Res Treat; 2019 Jan; 173(1):103-109. PubMed ID: 30238273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
    Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
    J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trials.
    Gyawali B; Niraula S
    Cancer Treat Rev; 2017 Nov; 60():18-23. PubMed ID: 28863313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer.
    McArthur HL; Mahoney KM; Morris PG; Patil S; Jacks LM; Howard J; Norton L; Hudis CA
    Cancer; 2011 Dec; 117(24):5461-8. PubMed ID: 21681735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.
    Perez EA; Romond EH; Suman VJ; Jeong JH; Sledge G; Geyer CE; Martino S; Rastogi P; Gralow J; Swain SM; Winer EP; Colon-Otero G; Davidson NE; Mamounas E; Zujewski JA; Wolmark N
    J Clin Oncol; 2014 Nov; 32(33):3744-52. PubMed ID: 25332249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.
    Perez EA; Dueck AC; McCullough AE; Chen B; Geiger XJ; Jenkins RB; Lingle WL; Davidson NE; Martino S; Kaufman PA; Kutteh LA; Sledge GW; Harris LN; Gralow JR; Reinholz MM
    J Clin Oncol; 2013 Jun; 31(17):2115-22. PubMed ID: 23650412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer.
    Hayashi N; Niikura N; Yamauchi H; Nakamura S; Ueno NT
    Breast Cancer Res Treat; 2013 Jan; 137(2):523-31. PubMed ID: 23184079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
    Untch M; von Minckwitz G; Gerber B; Schem C; Rezai M; Fasching PA; Tesch H; Eggemann H; Hanusch C; Huober J; Solbach C; Jackisch C; Kunz G; Blohmer JU; Hauschild M; Fehm T; Nekljudova V; Loibl S;
    J Clin Oncol; 2018 May; 36(13):1308-1316. PubMed ID: 29543566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831.
    Crozier JA; Moreno-Aspitia A; Ballman KV; Dueck AC; Pockaj BA; Perez EA
    Cancer; 2013 Jul; 119(13):2447-54. PubMed ID: 23585192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis.
    Inno A; Barni S; Ghidini A; Zaniboni A; Petrelli F
    Breast Cancer Res Treat; 2019 Jan; 173(2):247-254. PubMed ID: 30317424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers.
    Horio A; Fujita T; Hayashi H; Hattori M; Kondou N; Yamada M; Adachi E; Ushio A; Gondou N; Sueta A; Yatabe Y; Iwata H
    Int J Clin Oncol; 2012 Apr; 17(2):131-6. PubMed ID: 21681642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J; Perez EA; Pienkowski T; Bell R
    Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
    Gianni L; Dafni U; Gelber RD; Azambuja E; Muehlbauer S; Goldhirsch A; Untch M; Smith I; Baselga J; Jackisch C; Cameron D; Mano M; Pedrini JL; Veronesi A; Mendiola C; Pluzanska A; Semiglazov V; Vrdoljak E; Eckart MJ; Shen Z; Skiadopoulos G; Procter M; Pritchard KI; Piccart-Gebhart MJ; Bell R;
    Lancet Oncol; 2011 Mar; 12(3):236-44. PubMed ID: 21354370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis.
    Stewart P; Blanchette P; Shah PS; Ye XY; Boldt RG; Fernandes R; Vandenberg T; Raphael J
    Breast; 2020 Dec; 54():203-210. PubMed ID: 33130486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup.
    D'Hondt V; Canon JL; Roca L; Levy C; Pierga JY; Le Du F; Campone M; Desmoulins I; Goncalves A; Debled M; Rios M; Ferrero JM; Serin D; Hardy-Bessard AC; Piot G; Brain E; Dohollou N; Orfeuvre H; Lemonnier J; Roché H; Delaloge S; Dalenc F
    Eur J Cancer; 2019 Nov; 122():91-100. PubMed ID: 31634648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer.
    He X; Ji J; Tian M; Esteva FJ; Hortobagyi GN; Yeung SJ
    Clin Cancer Res; 2019 Dec; 25(24):7388-7395. PubMed ID: 31515457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.